Phase Ib/II Trial of QLC5508 and QLH12016 in Advanced Prostate Cancer
A Phase Ib/II clinical trial is underway to evaluate QLC5508 and QLH12016 in combination with other therapies for advanced prostate cancer.
Company
Pharmaceutical intelligence for QLC Biotech with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.